查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836927

呼吸系統疾病檢測市場按檢測類型、成分、年齡層、技術、檢測目的、疾病類型和最終用戶分類－2025-2032 年全球預測

Respiratory Disease Testing Market by Test Type, Component, Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，呼吸系統疾病檢測市場將成長至 104.3 億美元，複合年成長率為 6.10%。

主要市場統計數據
基準年2024年 64.9億美元
預計2025年 68.6億美元
預測年份：2032年 104.3億美元
複合年成長率（%） 6.10%

現代呼吸檢測生態系統的框架以及組織必須應對的策略挑戰，以協調診斷、交付模式和患者需求

呼吸系統檢測領域正經歷快速發展，這得歸功於日益融合的臨床需求、技術進步以及醫療服務模式的轉變。本報告概述了重新定義住院、門診和居家環境中檢測設計、交付和使用方式的促進因素。報告重點關注血液檢測、影像學檢查和肺功能評估等診斷模式，並強調了儀器、耗材和軟體解決方案之間相互作用，從而支持現代化的工作流程。

臨床醫生和實驗室管理人員日益尋求能夠加快獲得可操作結果、與電子健康記錄整合並支援遠端監控途徑的診斷解決方案。同時，支付方和醫療系統也優先考慮能夠提高病患管理效率並實現早期療育。這些壓力與分子診斷和先進影像技術的成熟同步出現，它們共同擴大了醫療保健提供者可獲得的具有臨床意義的診斷結果的範圍。

本章將闡明利害關係人必須回答的核心問題，為後續的深入分析奠定基礎：如何使採購和研發重點與相關人員群體的需求保持一致，如何管理試劑和設備供應鏈的複雜性，以及如何大規模運作先進的檢測技術。本書將幫助讀者理解後續章節，探討結構性變化、關稅影響、細分市場細微差別、區域動態、競爭行動以及可行的策略步驟。

一項重大的產業轉型，透過分散化、軟體整合和策略夥伴關係關係重新定義測試範式，重塑臨床工作流程

呼吸系統疾病檢測領域正因臨床、供應架構和技術能力的變革而再形成。變革的關鍵載體之一是床邊診斷和家用診斷的加速發展，這使得檢測從集中式實驗室轉移到需要便攜性、易用性和連接性的分散式醫療機構。隨著支援長時間重複、低侵入性測量的設備和檢測的興起，這種分散化趨勢推動了對縱向監測的關注。

同時，演算法影像分析和雲端讀取平台正在增強影像工作流程，縮短讀取時間，並催生外包讀取和影像即服務等新服務。分子診斷已拓展其臨床應用範圍和技術穩健性，實現了多重檢測和高靈敏度檢測，從而實現更早的干涉。雖然試劑和套件的創新仍然是差異化優勢，但從儀器控制到結果解讀和報告的軟體整合正成為決定性的競爭優勢。

供應鏈的韌性和監管的完整性也正在改變製造商和供應商的產品設計和上市方式。儀器製造商、試劑供應商和軟體供應商之間正在建立戰略夥伴關係，透過提供整合解決方案而非單一組件來簡化採購流程並支援端到端臨床工作流程。總而言之，這些轉變需要製定靈活的商業策略，並將臨床需求與產品藍圖緊密結合。

全面評估近期關稅政策如何影響整個診斷價值鏈的籌資策略、採購行為和供應鏈彈性

美國加徵關稅的累積效應正在為呼吸偵測供應鏈的各個環節帶來壓力，影響採購決策、採購週期和成本結構。診斷設備和耗材進口關稅的變化促使製造商和經銷商重新評估其生產佈局和供應商多元化策略，這通常會加速考慮近岸外包和跨區域採購，以減少在單一國家/地區的業務風險。這種動態需要在接近性、人事費用、合規成本以及快速試劑補充所需的物流敏捷性之間進行權衡。

為應對這項挑戰，一些供應商優先考慮在岸組裝，確保區域製造基地以降低運輸相關延誤和關稅波動帶來的風險，並協商長期供應協議以對沖價格波動。醫療保健機構和實驗室正在透過延長採購前置作業時間和盡可能整合供應商來應對這項挑戰。透明的整體擁有成本分析至關重要，相關人員現在必須將與關稅相關的情境納入採購評估和臨床規劃中。

監管和報銷方面的考慮進一步加劇了關稅的影響。當投入成本上升導致單次檢測支出增加時，監管機構和付款方可能會更嚴格地審查臨床效用，而醫療服務提供者可能會優先考慮那些能夠明顯改善護理路徑的檢測。因此，公司必須透過清晰的價值陳述、營運效益以及改善的療效和效率抵消成本增加的證據來證明價格調整的合理性。

詳細的細分觀點揭示了診斷產品設計、臨床效用和商業化如何與測試模式、技術和最終用戶保持一致

透過按檢測類型、組件、年齡層、技術、檢測目標、疾病類型和最終用戶對市場進行分析，細分市場層面的分析揭示了整個檢測生態系統中差異化的商業機會和營運需求。根據檢測類型，重點關注包含生化和免疫學測量的血液檢測、用於結構評估的影像檢查（包括胸部X光和電腦斷層掃描）以及用於量化呼吸動態的肺功能測試。儀器、試劑/套件和軟體的性能和市場策略因組件而異，例如，儀器需要資本規劃，試劑需要低溫運輸物流和批次管理，而軟體需要互通性和生命週期更新。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大基於 CRISPR 的照護現場方法，快速檢測呼吸道病原體
  • 引入人工智慧驅動的演算法來預測臨床環境中的呼吸道感染疾病風險
  • 引進遠端醫療整合家庭檢體套件，增強遠距呼吸診斷能力
  • 醫院實驗室擴大使用多重 PCR 檢測新出現的空氣傳播病原體變體
  • 擴大使用穿戴式呼吸分析設備來即時、持續地監測呼吸生物標記
  • 推出雲端連接檢測平台，用於即時監測呼吸道感染疾病疫情
  • 新興市場中，紙基橫向流動化驗在低成本呼吸道病毒篩檢的應用日益普及
  • 用於全面分析呼吸道微生物組和發現病原體的新興次世代定序工作流程

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 呼吸系統疾病檢測市場（依檢測類型）

  • 血液檢查
  • 影像檢查
    • 胸部X光檢查
    • 電腦斷層掃描
  • 肺功能檢查

9. 呼吸系統疾病檢測市場（按組件）

  • 裝置
  • 試劑和套件
  • 軟體

第 10 章呼吸系統疾病檢測市場（依年齡層）

  • 成人
  • 老年人
  • 孩子們

第 11 章呼吸系統疾病檢測市場（按技術）

  • 成像技術
  • 免疫檢測
  • 微生物學
  • 分子診斷

第12章呼吸系統疾病檢測市場（依檢測目的）

  • 診斷
  • 監控
  • 預後
  • 篩檢

第13章呼吸系統疾病檢測市場（依疾病類型）

  • 氣喘
  • 慢性阻塞性肺病（COPD）
    • 慢性支氣管炎
    • 氣腫
  • 傳染性呼吸道疾病
    • 流感
    • 肺炎
    • 結核
  • 肺癌

第 14 章呼吸系統疾病檢測市場（按最終用戶）

  • 診斷實驗室
  • 居家照護環境
  • 醫院和診所
  • 研究辦公室

第 15 章呼吸系統疾病檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章呼吸系統疾病檢測市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章呼吸系統疾病檢測市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • AstraZeneca PLC
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Biomerieux PLC
    • Charles River Laboratories
    • COSMED srl
    • Eurofins Viracor, LLC
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings
    • GE Healthcare
    • Koninklijke Philips NV
    • Medtronic PLC
    • MGC Diagnostics Corporation by Caire Inc.
    • QIAGEN Group
    • ResMed
    • SDI Diagnostics, Inc.
    • Seegene Inc.
    • Seimens Healthineers AG
    • Thermo Fisher Scientific
Product Code: MRR-035AB9C0DAAD

The Respiratory Disease Testing Market is projected to grow by USD 10.43 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.49 billion
Estimated Year [2025] USD 6.86 billion
Forecast Year [2032] USD 10.43 billion
CAGR (%) 6.10%

Framing the modern respiratory testing ecosystem and the strategic questions organizations must address to align diagnostics, delivery models, and patient needs

The respiratory disease testing environment is undergoing a period of rapid evolution driven by converging clinical needs, technological advances, and shifting care delivery models. This introduction distills the driving forces that are redefining how testing is designed, delivered, and consumed across inpatient, outpatient, and home-based settings. It frames the report's focus on diagnostic modalities that span blood assays, imaging, and pulmonary function evaluation while highlighting the interplay between instruments, consumables, and software solutions that enable modern workflows.

Clinicians and laboratory managers are increasingly demanding diagnostic solutions that reduce time to actionable result, integrate with electronic health records, and support remote monitoring pathways. At the same time, payers and health systems are prioritizing tests that improve patient management efficiency and enable earlier intervention. These pressures are occurring alongside technological maturation in molecular diagnostics and advanced imaging analytics, which together expand the range of clinically meaningful outputs available to providers.

This section sets the context for the deeper analysis that follows by articulating the core questions stakeholders must answer: how to align procurement and R&D priorities with patient population needs, how to manage supply chain complexity for reagents and instruments, and how to operationalize advanced testing technologies at scale. It prepares readers to interpret subsequent chapters that examine structural shifts, tariff impacts, segmentation nuances, regional dynamics, competitive behavior, and actionable strategy steps.

Critical industry transformations redefining testing paradigms through decentralization, software integration, and strategic partnerships that reshape clinical workflows

The landscape for respiratory disease testing is being reshaped by transformative shifts that cut across clinical practice, supply architecture, and technological capability. One primary vector of change is the acceleration of point of care and home-based diagnostics, which relocates testing out of centralized labs and into decentralized care settings that demand portability, ease of use, and connectivity. This decentralization is accompanied by stronger emphasis on longitudinal monitoring, which elevates devices and assays that can support repeated, low-burden measurements over time.

Concurrently, imaging workflows are being augmented by algorithmic image analysis and cloud-enabled reading platforms that compress interpretation timelines while creating novel services such as outsourced reads and imaging-as-a-service. Molecular diagnostics have expanded in clinical breadth and technical robustness, enabling multiplexed panels and high-sensitivity detection that informs earlier interventions. Reagent and kit innovation continues to be a differentiator, but the integration of software, from instrument control to result interpretation and reporting, is becoming a decisive competitive axis.

Supply chain resilience and regulatory alignment are also shifting how manufacturers and providers approach product design and market entry. Strategic partnerships between device makers, reagent suppliers, and software vendors are emerging to deliver integrated solutions rather than discrete components, thereby simplifying procurement and supporting end-to-end clinical workflows. Taken together, these shifts demand adaptive commercial strategies and closer alignment between clinical needs and product roadmaps.

Comprehensive assessment of how recent tariff policies have redirected sourcing strategies, procurement behavior, and supply chain resilience across the diagnostic value chain

The cumulative effect of tariff actions initiated in the United States has exerted pressure across multiple dimensions of the respiratory testing supply chain, influencing sourcing decisions, procurement cycles, and cost structures. Changes to import duties on diagnostic instruments and consumables have incentivized manufacturers and distributors to reassess manufacturing footprints and supplier diversification strategies, often accelerating exploration of nearshoring and multi-region sourcing to mitigate single-country exposure. This dynamic creates tradeoffs between proximity, labor and compliance costs, and the logistical agility needed for rapid reagent replenishment.

In response, some vendors are prioritizing onshore assembly or regional production hubs that reduce transit-related delays and exposure to tariff volatility, while others are negotiating long-term supply agreements that hedge pricing risk. Health systems and laboratories are reacting by lengthening lead times on procurement and by intensifying vendor consolidation efforts where feasible, seeking the predictability of bundled contracts even as they weigh the impact of higher landed costs. The need for transparent total cost of ownership analysis has become paramount; stakeholders must now incorporate tariff-related scenarios into procurement evaluations and clinical planning.

Regulatory and reimbursement considerations further compound the effects of tariffs. When elevated input costs translate into higher per-test expenditures, regulatory bodies and payers may scrutinize clinical utility more closely, and providers may prioritize tests that demonstrably improve care pathways. Consequently, companies will need to justify price adjustments with clear value narratives, operational benefits, and evidence that offsets cost increases through improved outcomes or efficiencies.

In-depth segmentation perspective revealing how diagnostic product design, clinical utility, and commercialization must align across test modalities, technologies, and end users

Segment-level analysis reveals differentiated opportunities and operational imperatives across the testing ecosystem when the market is parsed by test type, component, age group, technology, test purpose, disease type, and end user. Based on test type, attention is divided between blood tests that enable biochemical and immunologic readouts, imaging tests that include chest X-ray and computed tomography for structural evaluation, and pulmonary function tests that quantify respiratory mechanics, each of which addresses distinct clinical decision points and operational requirements. Based on component, performance and go-to-market strategies vary substantially for instruments, reagents and kits, and software, with instruments requiring capital planning, reagents demanding cold-chain logistics and lot management, and software hinging on interoperability and lifecycle updates.

Based on age group, clinical utility and product design must account for adults, geriatrics, and pediatrics, as each cohort presents unique sampling, compliance, and interpretative considerations. Based on technology, opportunities cluster around imaging technologies that deliver structural insights, immunoassays that offer targeted biomarker detection, microbiology platforms that support culture and organism identification, and molecular diagnostics that enable high-sensitivity nucleic acid detection. Based on test purpose, solutions differ markedly when oriented toward diagnosis, monitoring, prognosis, or screening, and product positioning must reflect the operational cadence and regulatory expectations inherent to each use case.

Based on disease type, product and service requirements align to clinical workflows for asthma, chronic obstructive pulmonary disease with its chronic bronchitis and emphysema subtypes, infectious respiratory diseases spanning influenza, pneumonia and tuberculosis, and lung cancer where staging and molecular profiling are central. Based on end users, diagnostic laboratories, home care settings, hospitals and clinics, and research laboratories each have distinct purchasing models, integration needs, and staffing capabilities that affect adoption pathways and support models. This segmentation framework clarifies where vendors should prioritize product enhancements, clinical validation efforts, and tailored go-to-market messaging.

Regional dynamics and market entry considerations that determine adoption, regulatory navigation, and supply chain configuration across major global healthcare regions

Regional dynamics significantly influence regulatory pathways, reimbursement environments, supply chain decisions, and adoption rates for respiratory disease testing innovations. In the Americas, healthcare delivery models and payer structures create a strong emphasis on demonstrating clinical utility and operational efficiency, driving demand for integrated diagnostic solutions that reduce downstream costs and support value-based care agreements. In Europe, Middle East and Africa, heterogeneity in regulatory frameworks and procurement practices necessitates flexible market entry strategies, localized clinical evidence generation, and partnerships with regional distributors to navigate reimbursement variability and capacity constraints.

In Asia-Pacific, rapid adoption of digital health infrastructure and significant investment in local manufacturing capacity create fertile conditions for scale-driven approaches, with governments and private health networks actively supporting diagnostic modernization initiatives. Cross-regional considerations include the need to tailor product configurations to local laboratory capabilities, to provide multilingual software interfaces, and to ensure that logistics models accommodate diverse cold-chain and customs environments. Additionally, companies must anticipate regional differences in disease prevalence, screening priorities, and clinical practice patterns when developing clinical validation strategies and commercial rollouts.

Taken together, geographic realities inform not only market access tactics but also R&D prioritization and manufacturing placement. Successful players adopt a regionally nuanced playbook that balances global platform efficiencies with locally adapted commercialization and service models to accelerate adoption and sustain operations across heterogeneous markets.

Strategic competitive behaviors and partnership models that drive differentiation through integrated platforms, evidence generation, and service excellence

Competitive behavior among companies in the respiratory diagnostics space is characterized by a mix of product specialization, platform expansion, and strategic collaborations that aim to deliver more complete clinical workflows. Instrument manufacturers continue to invest in modular platforms that support both core testing capabilities and future assay expansion, while reagent and kit suppliers focus on robustness, supply consistency, and simplified handling to lower the operational burden on laboratories and point of care settings. Software providers are increasingly differentiating through advanced analytics, connectivity to electronic health records, and features that support remote monitoring and telehealth integration.

Partnerships between device makers and software firms are producing bundled offerings that reduce integration friction and present a clearer value proposition to hospitals and diagnostic networks. Concurrently, joint development agreements with clinical research organizations and academic institutions are being used to build evidence for new assay claims and to accelerate regulatory submissions. Service and aftermarket offerings, such as managed reagent programs and remote instrument diagnostics, have become important revenue streams and customer retention levers. Companies that can demonstrate end-to-end reliability, rapid support response, and a clear pathway for clinical adoption are more likely to secure long-term contracts with health systems.

To compete effectively, firms must balance investments in core technological excellence with pragmatic commercial execution, investing in field service capabilities, training programs for clinical staff, and outcome-oriented evidence generation that resonates with procurement and clinical decision makers.

Concrete strategic initiatives that industry executives can implement to strengthen adoption, resilience, and commercial value across diagnostic portfolios

Industry leaders seeking to accelerate growth and build defensible positions in respiratory testing should pursue a set of pragmatic, actionable steps that align product development, go-to-market strategy, and operational resilience. First, prioritize interoperability and data integration capabilities so that instruments and software can plug into existing hospital systems and reporting workflows; this reduces adoption friction and supports clinical decision making. Second, strengthen supply chain diversification by qualifying secondary suppliers, exploring regional production partnerships, and implementing inventory strategies that buffer against tariff and logistics shocks.

Third, invest in clinical evidence that ties test results to measurable care improvements and operational savings; health systems and payers respond to clear demonstrations of value through changed clinical pathways. Fourth, design product lines with modularity in mind so that customers can scale offerings by purchasing incremental capabilities rather than replacing capital equipment. Fifth, expand service offerings to include managed reagents, remote maintenance, and training that reduce the operational burden on end users and create recurring revenue streams. Finally, adopt flexible commercial models-such as outcome-linked pricing, subscription access to software, and bundled solutions-that match the capital and operational constraints of different end users.

These actions should be executed in a coordinated manner across R&D, regulatory, commercial, and supply chain functions to ensure consistent messaging and efficient delivery of value to providers and patients.

Transparent mixed methods research design combining stakeholder interviews, technical validation, and scenario analysis to underpin the respiratory diagnostics findings

The research approach underpinning this analysis blended structured primary research with rigorous secondary synthesis and iterative triangulation to ensure accuracy and relevance. Primary inputs included in-depth interviews with clinical leaders, laboratory directors, procurement professionals, and industry executives to capture firsthand perspectives on adoption barriers, workflow constraints, and purchasing criteria. These qualitative insights were complemented by technical discussions with product development and supply chain specialists to understand manufacturing realities, reagent handling requirements, and software integration challenges.

Secondary research encompassed review of regulatory guidance, clinical literature, and public policy documents to contextualize technology adoption and reimbursement frameworks. Data synthesis applied cross-validation techniques that compared manufacturer claims, clinical protocol expectations, and end-user operational constraints to build a coherent narrative about where innovation is translating into practice. The methodology also incorporated scenario analysis to illuminate how policy shifts, such as tariff changes and regulatory updates, might alter strategic choices for manufacturers and providers.

Limitations are acknowledged where proprietary contractual terms and confidential supplier arrangements restrict visibility; where possible, the analysis highlights risk factors and suggests information gaps for future primary inquiry. Overall, the methodology emphasizes transparency, stakeholder diversity, and methodological rigor to support defensible conclusions and actionable recommendations.

Synthesis of diagnostic ecosystem drivers and strategic priorities that leaders must address to capitalize on innovation while managing operational and policy risks

In conclusion, the respiratory disease testing landscape is transitioning toward integrated solutions that blend robust instrumentation, reliable reagents, and intelligent software to meet evolving clinical and operational needs. Decentralization of testing and the rise of longitudinal monitoring change the calculus for product design, favoring portability, connectivity, and ease of use. Tariff dynamics and supply chain considerations add another layer of strategic complexity, compelling organizations to rethink manufacturing placement, supplier relationships, and procurement practices to preserve cost-effectiveness and continuity of supply.

Segmentation analysis highlights that different test types, technologies, disease targets, and end users require distinct value propositions and commercialization approaches. Regional differences further necessitate tailored market access plans and localized evidence generation. Competitive differentiation increasingly rests on the ability to deliver end-to-end value through service models, clinical validation, and interoperable platforms. For stakeholders across the ecosystem, success will be determined by the agility to adapt product strategies to clinical workflows, the foresight to manage supply chain exposure, and the commitment to generate evidence that resonates with clinicians and payers alike.

The insights presented here are intended to inform strategic planning, guide tactical investments, and support cross-functional alignment as organizations navigate the complex and rapidly changing respiratory diagnostics environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of CRISPR-based point-of-care assays for rapid detection of respiratory pathogens
  • 5.2. Deployment of AI-driven algorithms for predictive respiratory infection risk assessment in clinical settings
  • 5.3. Adoption of telehealth-integrated home sampling kits enhancing remote respiratory diagnostics capabilities
  • 5.4. Growth of multiplex PCR panels targeting emerging airborne pathogen variants in hospital laboratories
  • 5.5. Rising use of wearable breath analysis devices for continuous monitoring of respiratory biomarkers in real time
  • 5.6. Implementation of cloud-connected testing platforms enabling real-time surveillance of respiratory outbreaks
  • 5.7. Increased development of paper-based lateral flow assays for low-cost respiratory virus screening in emerging markets
  • 5.8. Emergence of next-generation sequencing workflows for comprehensive respiratory microbiome profiling and pathogen discovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Respiratory Disease Testing Market, by Test Type

  • 8.1. Blood Tests
  • 8.2. Imaging Tests
    • 8.2.1. Chest X-Ray
    • 8.2.2. Computed Tomography
  • 8.3. Pulmonary Function Tests

9. Respiratory Disease Testing Market, by Component

  • 9.1. Instruments
  • 9.2. Reagents & Kits
  • 9.3. Software

10. Respiratory Disease Testing Market, by Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Respiratory Disease Testing Market, by Technology

  • 11.1. Imaging Technologies
  • 11.2. Immunoassays
  • 11.3. Microbiology
  • 11.4. Molecular Diagnostics

12. Respiratory Disease Testing Market, by Test Purpose

  • 12.1. Diagnosis
  • 12.2. Monitoring
  • 12.3. Prognosis
  • 12.4. Screening

13. Respiratory Disease Testing Market, by Diseases Type

  • 13.1. Asthma
  • 13.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 13.2.1. Chronic Bronchitis
    • 13.2.2. Emphysema
  • 13.3. Infectious Respiratory Diseases
    • 13.3.1. Influenza
    • 13.3.2. Pneumonia
    • 13.3.3. Tuberculosis
  • 13.4. Lung Cancer

14. Respiratory Disease Testing Market, by End Users

  • 14.1. Diagnostic Laboratories
  • 14.2. Home Care Settings
  • 14.3. Hospitals & Clinics
  • 14.4. Research Laboratories

15. Respiratory Disease Testing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Respiratory Disease Testing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Respiratory Disease Testing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. AstraZeneca PLC
    • 18.3.3. Becton, Dickinson and Company
    • 18.3.4. Bio-Rad Laboratories, Inc.
    • 18.3.5. Biomerieux PLC
    • 18.3.6. Charles River Laboratories
    • 18.3.7. COSMED srl
    • 18.3.8. Eurofins Viracor, LLC
    • 18.3.9. F. Hoffmann-La Roche Ltd.
    • 18.3.10. Fujifilm Holdings
    • 18.3.11. GE Healthcare
    • 18.3.12. Koninklijke Philips N.V
    • 18.3.13. Medtronic PLC
    • 18.3.14. MGC Diagnostics Corporation by Caire Inc.
    • 18.3.15. QIAGEN Group
    • 18.3.16. ResMed
    • 18.3.17. SDI Diagnostics, Inc.
    • 18.3.18. Seegene Inc.
    • 18.3.19. Seimens Healthineers AG
    • 18.3.20. Thermo Fisher Scientific

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)

TABLE 29